Stocks
Neurocrine Biosciences (NBIX) Debt/EBITDA US GAAP (year values) |
|||||||||
| 2021 | 2022 | 2023 | 2024 | 2025 | LTM ? | CAGR 5 years ? | |||
| Debt/EBITDA | -1.96 | -2.75 | -1.45 | -0.97 | -1.60 | -1.03 | |||
| Changes by years, y/y, % | +70% | +40% | -47% | -33% | +65% | +6.7% | |||
Neurocrine Biosciences. Debt/EBITDA
Neurocrine Biosciences. Debt/EBITDA, changes, %
Neurocrine Biosciences (NBIX) Debt/EBITDA US GAAP (quarter values) |
||||||||
| 2025Q1 | 2025Q2 | 2025Q3 | 2025Q4 | 2026Q1 | LTM ? | |||
| Debt/EBITDA | -0.89 | -0.96 | -0.31 | -1.48 | -1.03 | -1.03 | ||
| Changes by years, y/y, % | -25% | -24% | -79% | +53% | +16% | |||
| Changes by quarters, q/q, % | -9% | +9% | -68% | +377% | -30% | |||
